Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Charles River Laboratories $295 million acquisition of Explora BioLabs Holdings
We advised Charles River on the transaction
Novo Nordisk insulin pricing litigation victory
We prevailed in having the complaint dismissed with prejudice
Owens & Minor $600 million notes offering
The high-yield notes are due 2030
AN2 Therapeutics $69 million IPO
The shares are listed on the Nasdaq Global Select Market
Roche Holdings $5 billion notes offering
We advised Roche on the Rule 144A / Regulation S offering comprising five tranches of notes
Denali $400 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
$12.6 billion financing for investor group acquisition of a software company
We advised the debt and preferred equity financing sources on the transaction
Signify Health $250 million acquisition of Caravan Health
We are advising Signify Health on the transaction
Silver Spike Acquisition Corp. II combination with Eleusis
We are advising the SPAC on the transaction
Smith+Nephew acquisition of Engage Surgical
We are advising Smith+Nephew on the transaction